Introduction
Prosthesis-patient mismatch (PPM) was first described over 30 years ago (Rahimtoola, 1978) for aortic valve replacement: when the in vivo effective orifice area (EOA) of the prosthetic valve is less than that of the native, non-diseased, human valve. Extensive documentation on the role of PPM after aortic valve replacement (AVR) particularly addresses left ventricular mass regression and patient survival. Controversy continues about the influence of PPM on patient survival, both early and late mortality. Many studies ( I t s h o u l d b e n o t e d t h a t t h e i n d i c a t i o n f o r s u r g i c a l m a n a g e m e n t o f a o r t i c s t e n o s i s i s symptomatic severe aortic stenosis (< 1.0 cm 2 valve area). In the majority of patients, this is equivalent to an EOAI at or below the level of severe mismatch by our definition.
The influence of PPM on postoperative patient outcomes
The objective of our study ) on 3,343 patients having AVR for severe aortic stenosis or mixed aortic stenosis/insufficiency was to determine the predictors for all levels of PPM on mortality and to determine if there is a relationship between PPM and other predictors of survival. The prostheses used were contemporary stented bioprostheses (2493) and mechanical prostheses (850). More specifically, 667 patients had CarpentierEdwards PERIMOUNT pericardial prostheses (Edwards Lifesciences, Irvine, CA), 1250 patients had Carpentier-Edwards supra-annular porcine prostheses, 576 patients had Medtronic Mosaic porcine prostheses (Medtronic, Minneapolis, MN), 462 patients had St. Jude Medical mechanical prostheses (St. Jude Medical, St. Paul, MN), and 388 patients had CarboMedics mechanical prostheses (Sorin-CarboMedics, Saluggia, Italy) ( Figure 1 ). There is a misconception with the Carpentier-Edwards supra-annular aortic valve for the early version (prior to 1985) of the mitral valve failed because of stent-post dehiscence due to excessive trimming of the aortic wall; however, this failure mode was identified in only one aortic prosthesis before the manufacturing trimming was changed (Jamieson et al., 2005; Jamieson et al, 2009 ). The level of PPM was classified for each patient based on reference EOAs and size for each prosthesis in the published literature. The patients considered for the study had their first aortic valve replacement. Patients who had a subsequent valvular replacement were censored alive on the date of the reoperative procedures. This concept was to avoid a hemodynamically different prosthesis at the time of reoperative explantation.
Carpentier-Edwards
Carpentier-Edwards Medtronic Mosaic SAV Perimount The conclusion by Mohty et al. that severe PPM is an independent predictor of late mortality in patients undergoing AVR differs from the conclusion by Jamieson et al. that PPM is not a predictor of survival. It should be noted that the severe PPM group consisted of 40 patients (1.6%) in the Mohty cohort whereas it consisted of 212 patients (6.3%) in the Jamieson cohort. The very small percentage of patients with severe PPM in the Mohty et al. study could be attributed to the fact that [1] only patients who survived through the short-term period following AVR were included (whereas all patients undergoing AVR was included in the Jamieson et al. study), and [2] the short-term mortality was much higher in the Mohty cohort (7 out of 27 patients with severe PPM, 25.9%), compared with the Jamieson cohort (6 out of 212, 2.8%), and therefore not as many patients in the severe PPM survived past the early period to be included in the Mohty et al. study. The finding of severe PPM as a significant predictor of survival may be purely related to the small group size. In other words, if the group had consisted of more patients, severe PPM may not have been found to be an independent predictor. The discrepancy between the findings of these two studies warrants further investigation. The predictors for late mortality, identified in a multivariate analysis in Jamieson et al. were age, male gender, NYHA functional class III/IV, concomitant coronary artery bypass, LVEF < 35%, BMI < 18, BMI > 35, bioprosthesis, preoperative congestive heart failure, diabetes mellitus, renal failure, and chronic obstructive pulmonary disease. In comparison, Mohty et al. (2009) found age, coronary artery disease, diabetes, renal failure, chronic lung disease, mechanical prosthesis, and severe PPM to be multivariate predictors of late mortality. Jamieson et al. found EOAI to have no predictive effect on survival, whether early, late, or overall, despite the survival curves differing by EOAI categories (38.1 ± 2.1% 15-year overall survival for no PPM, 37.0 ± 2.2% for mild-to-moderate PPM, and 22.1 ± 6.5% for severe PPM). The reasons for the differences in survival curves are related to the complexity of the patients in the three categories, especially the category of severe PPM for ≤ 60 years and ejection fraction ≤ 50%, rather than a direct contribution from PPM. Survival was adjusted in Jamieson et al. to determine the effect of covariates (EOAI, age, BMI, and EF). Severe EOAI had no relationship on adjusted survival for the evaluated covariates, except for very low level of significance for EF > 50%.
The influence of BMI was further evaluated (Yamashita et al., personal communication). Overweight or mild-to-moderately obese patients had a lower risk of early mortality, while underweight and severely obese patients had a higher risk of late mortality. When patients were analyzed as normal/underweight or overweight/obese, those with a normal EOAI had better 15-year survival than those with severe PPM. After adjusting for EOAI, age > 60 years and EF ≤ 50% indicated a higher risk of overall (early + late) mortality within BMI categories. These results suggest that BMI is associated with survival after AVR and that PPM may modify the effect. 2 , and that severe PPM reduces survival for patients with an ejection fraction > 50% but not for those with an EF ≤ 50% ( Figure 5 ). In comparison, Mohty et al. found that severe PPM was associated with increased mortality in patients < 70 years old but not in older patients, and that it significantly affected survival in patients with a BMI < 30kg/m 2 but not in those with a BMI ≥ 30kg/m 2 ( Figure 6A , 6B, 6C, 6D). They also found moderate-to-severe PPM to be an independent predictor of late mortality in patients with a pre-operative LVEF < 50% but not in those with preserved LV systolic function ( Figure 6E, 6F) . With regard to these discrepancies, it is worth noting that there were only 21 patients in the Jamieson et al. BMI < 25 kg/m 2 severe PPM group and 39 patients in the LVEF ≤ 50% severe PPM group, while for the severe PPM subset of the Mohty cohort, there were fewer than 20 patients in each of the < 70 years old, ≥ 70 years old, BMI < 30 kg/m 2 , and BMI ≥ 30kg/m 2 subgroups. We therefore believe that the discrepancies in the above results may be purely due to random variations in the small data sets, and that if given an adequate number of cases in each of the categories, there may be no differences in the results between the Jamieson et al. and the Mohty et al. groups. Ruel et al. (2006) found that PPM primarily affected patients with impaired left ventricular function at the time of AVR, and patients in whom PPM was associated with decreased overall long-term survival, lower freedom from heart failure, and diminished left ventricular mass regression. Also, an EOAI ≤ 0.85 cm 2 / m 2 did not have a significantly detrimental effect in patients with normal preoperative left ventricular function. However, the authors pointed out that PPM might have been found to have a significant effect in the normal LV function cohort had they evaluated cases with severe mismatch (≤ 0.65 cm 2 / m 2 ). An earlier study by Ruel et al. (2004) had shown that although PPM had significant effects on cardiac end points (occurrence of congestive heart failure, etc), it had no effect on overall survival after AVR. Kulik et al. (2006) found that patients with low-gradient aortic stenosis (LGAS, defined as an aortic valve area of < 1.2cm 2 , a mean transvalvular pressure gradient of < 40 mmHg, and a LVEF of < 50%) have worse long-term outcomes after AVR, and that PPM further adversely affects the long-term outcomes of LGAS patients and should therefore be avoided in this population. 1055 745  479  284 153  68  383 285  187  99  49  20  14  12  8  5  4  1   232 154  83  46  23  9  212 160 107  61  30  17  16  11  8  6  5  2 www.intechopen.com (Higgins et al., 2011 ) that evaluated the influence of gender on early, late, and overall survival reported that the predictors of mortality after AVR for aortic stenosis differed between male and female patients. Female gender was a predictor of early mortality while male gender was a predictor of late (but not early or overall) mortality. Male gender increased the risk of late mortality, and a valve size ≤ 21 mm increased the risk of early and overall mortality among male patients only. These differences need to be taken into consideration preoperatively and require consideration during operative management. The Jamieson et al. analysis indicated that severe PPM identified with an EOAI < 0.65 cm 2 /m 2 is not an independent predictor of early mortality, late mortality, or overall mortality after AVR. These findings have been discussed in perspective with other studies that have and have not provided evidence of PPM as an independent predictor of survival. The independent influence of bioprostheses as a risk factor of late and overall mortality also needs extensive evaluation because currently bioprostheses are recommended for patients ≥ 60 years old to minimize serious valve-related morbidity and provide a relatively acceptable degree of valve-related reoperation for structural valve deterioration. 
A suggested approach to PPM
Because the negative impact of severe PPM on postoperative survival, it is crucial to avoid leaving patients with severe PPM after valvular surgery. Pibarot and Dumesnil (2000) presented a 3-step approach for preventing PPM: [1] calculate the patient's body surface area from weight and height; [2] using a BSA versus EOAI In agreement with the above, despite failing to find severe PPM (< 0.65 cm 2 / m 2 ) as an independent predictor of early, late, or overall mortality after AVR, we recommend that surgeons do not leave patients with a severe mismatch (especially for bioprostheses, which may develop degenerative changes over time that would further reduce the EOAI). Surgeons should maintain a prospective strategy of implanting an adequately sized aortic prosthesis that will preclude patients from being in the category of severe mismatch (near equivalent to indications for intervention in severe aortic stenosis). However, a significant portion of patients undergoing AVR will have some level of mild-to-moderate PPM owing to the intrinsic obstructive nature of most prostheses, and should provide some confidence to surgeons and cardiologists that mild-to-moderate PPM is unlikely to be detrimental to survival. Other than selecting a prosthesis with sufficient EOA, as described above, there are several more intraoperative options available to surgeons to prevent the occurrence of severe PPM. Aortic root enlargement may be considered in patients with an elevated risk of developing moderate-to-severe PPM at time of valvular replacement surgery (Mohty et al., 2006) . Kulik et al. (2008) were able to insert larger prosthetic valves and achieve lower PPM by doing aortic root enlargement (ARE) at the time of AVR. They reported that the addition of an ARE to AVR increased the aortic cross-clamp time by 9.9 minutes, on average, and that there was no significant increase in perioperative morbidity or mortality associated with the added ARE. However, the lower incidence of PPM did not significantly affect long-term outcomes in their AVR + ARE cohort, once again coming back to the question of whether PPM significantly affects survival. The third option is a total aortic root replacement. Compared with a traditional stented bioprosthesis, total root replacement allows for optimal hemodynamics with no significant aortic regurgitation, improved regression of the LV mass, and less PPM in the small aortic root (Kon et (Girard et al., 2001 ). In Girard et al., there were no 30-day deaths for reoperations on 12 patients with isolated, severe PPM. However, 5 of the 9 patients who underwent concomitant major cardiac procedures at the time of valvular replacement died in-hospital, so there is a risk to reoperation. The benefit of relief from PPM must be weighed carefully against the risks of reoperation, and must be assessed on a patient-by-patient basis. When evaluating patients with mild-to-moderate PPM for the possibility of reoperation, we suggest that surgeons take into account the Jamieson et al. (2010) finding of the unlikelihood of mild-to-moderate PPM contributing to worse survival. From the accumulated data from published literature, it is easy to see that the topic of prosthesis-patient mismatch remains controversial. The issue is further complicated by the fact that there are several levels of PPM (nonsignificant, mild, moderate, or severe), with different studies showing different outcomes for each level of PPM. There is also currently no clear consensus on the exact definitions of PPM and its categories.
A sensible approach to the issue of PPM is that we should avoid generalizations for any given level of PPM except for severe PPM, for which the data in the existing literature is more consistent; therefore, proactive measures should be taken to prevent its occurrence. For other levels of PPM, it is reasonable to evaluate each patient on an individual basis (i.e., moderate PPM being more acceptable for a sedentary elderly patient, but less so for someone who is younger and more active), and for surgical and postoperative management options to be dependent on the individualized assessment.
